# Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)

> **NCT00557817** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Liege** · enrollment: 125 (actual)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** Darbepoetin alpha (Aranesp)
- **DRUG:** Iron saccharate (Venofer)

## Key facts

- **NCT ID:** NCT00557817
- **Lead sponsor:** University of Liege
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2010-01-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00557817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00557817, "Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00557817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*